Table 1.
Summary of the 19 performance indicators
| Indicator | Item | Numerator | Denominator |
|---|---|---|---|
| S1 | Rate of municipalities conducting hepatitis screening (through the Health Promotion Service) | Number of municipalities conducting hepatitis screening 1) | Number of municipalities 8) |
| S2 | Hepatitis screening rate per 100,000 adults aged 40 years or older (through the Health Promotion Service, calculated separately for HBV and HCV) | Number of people screened for hepatitis (through the Health Promotion Service) 2) | 100,000 individuals in the total population aged 40 years or older 9) |
| S3 | Hepatitis screening rate per 100,000 adults (through the Specific Infectious Disease Testing Service, calculated separately for HBV and HCV) | Number of people screened for hepatitis (through the Specific Infectious Disease Testing Service) 3) | 100,000 individuals in the total adult population 9) |
| S4 | Liver cancer incidence (morbidity) per 100,000 population (crude and age-adjusted) | Number of people with liver cancer 4) | 100,000 population |
| S5 | Liver cancer mortality per 100,000 population (crude and age-adjusted) | Number of deaths from liver cancer 5) | 100,000 population |
| S6 | Usage rate of subsidies for nucleos(t)ide analog therapy for hepatitis B | Number of patients receiving subsidy for nucleos(t)ide analog therapy 6) | Number of patients treated for hepatitis B (hepatitis and compensated or uncompensated cirrhosis) in FY2018 according to a FY2020 study based on a national database 10) |
| S7 | Usage rate of subsidies for DAA therapy for hepatitis C | Number of patients receiving subsidies for DAA therapy 6) | Number of patients treated for hepatitis C (hepatitis and compensated or uncompensated cirrhosis) in FY2018 according to a FY2020 study based on a national database 10) |
| FU1 | Usage rate of subsidies for initial detailed examinations per 100,000 adults | Number of individuals who received subsidies for initial detailed examinations 7) | 100,000 individuals in the total adult population 9) |
| FU2 | Rate of municipalities conducting follow-up | Number of municipalities conducting follow-up 1) | Number of municipalities 8) |
| FU3 | Usage rate of subsidies for periodic examinations per 100,000 adults | Number of individuals in each prefecture receiving subsidies for periodic examinations | 100,000 individuals in the total adult population 9) |
| P1 | Whether or not the prefecture had created a plan and numerical targets for countermeasures against hepatitis 1) | N/A | N/A |
| P2 | Whether or not the prefecture’s council responsible for hepatitis countermeasures held meetings 1) | N/A | N/A |
| P3 | Total number of certified hepatitis medical care coordinators (HMCCs) per 100,000 adults | Total number of certified HMCCs1) | 100,000 individuals in the total adult population 9) |
| P4 | Number of newly certified HMCCs per 100,000 adults in each year | Number of newly certified HMCCs a year 1) | 100,000 individuals in the total adult population 9) |
| P5 | Whether or not the local government had a system for renewing HMCC certification 1) | N/A | N/A |
| P6 | HMCC staffing rate at regional core centers for the management of liver disease | Number of regional core centers with at least one HMCC 1) | Number of regional core centers 1) |
| P7 | HMCC staffing rate at institutions specialized in liver diseases | Number of institutions specialized in liver diseases with at least one HMCC 1) | Number of institutions specialized in liver diseases |
| P8 | HMCC staffing rate at public health centers | Number of public health centers with at least one HMCC 1) | Number of public health centers 1) |
| P9 | HMCC staffing rate at municipal governments | Number of municipal governments with at least one HMCC 1) | Number of municipalities 8) |
The data sources used to calculate indicators 1) through 10) are listed in the Supplementary Information
HBV hepatitis B virus, HCV hepatitis C virus, DAA direct-acting antivirals, HMCC hepatitis medical care coordinators, N/A not applicable